Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.
暂无分享,去创建一个
T. Welte | A. O'donnell | W. Boersma | H. Tiddens | N. Sverzellati | C. Feldman | F. Blasi | M. Martínez-García | A. Torres | H. Al-Jahdali | C. Haworth | A. Barker | A. Hill | Conroy A Wong | J. Chalmers | S. Aliberti | M. Loebinger | M. Crichton | Thomas Vandendriessche | L. Morgan | P. Goeminne | A. De Soyza | G. Tino | M. Shteinberg | T. Aksamit | M. Vendrell | K. Dimakou | F. Ringshausen | E. Polverino | R. Menéndez | Jennifer J Meerburg | S. Elborn | Robert Wilson | M. Murris | T. Vandendriessche | J. J. Meerburg
[1] O. Sibila,et al. A CLUSTER ANALYSIS OF BRONCHIECTASIS PATIENTS BASED ON THE AIRWAY IMMUNE PROFILE. , 2020, Chest.
[2] H. Goossens,et al. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study , 2020, European Respiratory Journal.
[3] H. Tiddens,et al. Diagnosis and quantification of bronchiectasis using computed tomography or magnetic resonance imaging: A systematic review. , 2020, Respiratory medicine.
[4] F. Lapi,et al. Prevalence and incidence of bronchiectasis in Italy , 2020, BMC Pulmonary Medicine.
[5] T. Welte,et al. Increasing bronchiectasis prevalence in Germany, 2009–2017: a population-based cohort study , 2019, European Respiratory Journal.
[6] S. Salvi,et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. , 2019, The Lancet. Global health.
[7] M. Surette,et al. A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome , 2019, Scientific Reports.
[8] J. Chalmers,et al. A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults , 2019, European Respiratory Review.
[9] Meilan K. Han,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.
[10] A. O'donnell,et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. , 2019, The Lancet. Respiratory medicine.
[11] R. Diel,et al. The economic burden of bronchiectasis – known and unknown: a systematic review , 2019, BMC Pulmonary Medicine.
[12] L. Dupont,et al. National Survey on the Management of Adult Bronchiectasis in Belgium , 2019, COPD.
[13] A. Agustí,et al. Clinical Fingerprinting: A Way to Address the Complexity and Heterogeneity of Bronchiectasis in Practice. , 2019, American journal of respiratory and critical care medicine.
[14] K. Rabe,et al. Economic burden of bronchiectasis in Germany , 2018, European Respiratory Journal.
[15] M. Tunney,et al. British Thoracic Society Guideline for bronchiectasis in adults , 2018, Thorax.
[16] C. Daley,et al. Characteristics and Health‐care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014 , 2018, Chest.
[17] P. Flume,et al. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity , 2018, The Lancet.
[18] M. Miravitlles,et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions , 2018, European Respiratory Journal.
[19] Christoph Gerlinger,et al. Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis , 2018, American journal of respiratory and critical care medicine.
[20] D. Obradović,et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis , 2018, European Respiratory Journal.
[21] J. Elborn,et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis , 2018, European Respiratory Journal.
[22] Katrin Roth,et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis , 2018, European Respiratory Journal.
[23] D. Obradović,et al. Standardised classification of the aetiology of bronchiectasis using an objective algorithm , 2017, European Respiratory Journal.
[24] T. Welte,et al. European Respiratory Society guidelines for the management of adult bronchiectasis , 2017, European Respiratory Journal.
[25] F. Blasi,et al. The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration , 2017, Breathe.
[26] T. Welte,et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research , 2017, European Respiratory Journal.
[27] Raúl San José Estépar,et al. Quantitative CT Measures of Bronchiectasis in Smokers , 2017, Chest.
[28] J. Chalmers,et al. Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For , 2017, Respiration.
[29] M. Mantero,et al. Quality standards for the management of bronchiectasis in Italy: a national audit , 2016, European Respiratory Journal.
[30] A. Torres,et al. Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. , 2015, Annals of the American Thoracic Society.
[31] J. M. Salge,et al. Aging of the Lungs in Asymptomatic Lifelong Nonsmokers: Findings on HRCT , 2015, Lung.
[32] N. Müller,et al. Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.
[33] M. Denton,et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. , 2003, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[34] Hideki Shima,et al. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. , 2003, AJR. American journal of roentgenology.